Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advancements research found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7,